1. Articles in category: Trials

    1-24 of 175 1 2 3 4 5 6 7 8 »
    1. Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Cormedix, Inc.: CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 26, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and other diseases, today announced that it received notification on Friday, February 23, 2018 that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to taurolidine for the treatment of neuroblastoma. Taurolidine is currently in preclinical development for neuroblastoma and is a key component in the Company's lead product, Neutrolin®, a novel anti-infective ...

      Read Full Article
      Mentions: Treatment
    2. CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma

      Neuroblastoma is a severe form of cancer that originates in certain types of nerve tissues and most often begins in the adrenal glands, which are the small glands on top of the kidneys. It can develop in the chest, stomach, neck, pelvis, or bones. Children ages five or younger are most commonly affected ...

      Read Full Article
      Mentions: Treatment
    3. Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Updated Data Confirms a Durable 75 Percent Overall Response Rate, by Blinded Independent Review, of Larotrectinib in Adults and Children with Tumors Harboring TRK Fusions

      Larotrectinib, a highly selective TRK kinase inhibitor, shows rapid, potent, and durable efficacy in both adult and pediatric patients with solid tumors that harbor TRK fusions, regardless of tumor type or patient age, according to results from three clinical trials published in the New England Journal of Medicine.

      Read Full Article
    4. Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

      PLoS Med. 2018 Feb;15(2):e1002505

      Authors: Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J

      Read Full Article
    5. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2304-2319

      Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

      Read Full Article
      Mentions: MYCN
    6. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

      Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.

      Biol Blood Marrow Transplant. 2018 Jan 04;:

      Authors: Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P

      Read Full Article
      Mentions: Refractory MYCN GvHD
    7. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    8. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

      Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

      Clin Cancer Res. 2017 Oct 02;:

      Authors: Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman A, Yu AL, Sondel PM

      Read Full Article
      Mentions: COG Immunotherapy
    9. Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy

      Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from […]

      The post Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy appeared first on Healthcanal.com.

      Read Full Article
      Mentions: Immunotherapy
    10. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    11. Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Results Indicate That Larotrectinib Is Effective as the First Novel Targeted Therapy to Show a Consistent Response across Multiple Tumor Types in Adult and Pediatric Patients

      Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented today at the annual meeting of the American Society of Clinical Oncology in Chicago.

      Read Full Article
    12. An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy

      Condition :   Very High Risk Neuroblastoma Interventions :   Radiation: 131I- mIBG;   Drug: Topotecan;   Drug: Thiotepa;   Procedure: Autologous stem cell transplant Sponsors :   Gustave Roussy, Cancer Campus, Grand Paris;   SIOPEN;   French National Cancer Institute Not yet recruiting - verified May 2017

      Read Full Article
    13. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma

      Perifosine is an alkylphospholipid analog that inhibits or modulates signaling through signal transduction pathways such as Akt, which is enhanced in neuroblastoma (NB) by activation of tyrosine kinase receptors. We conducted a phase I study of perifosine in Japanese patients with recurrent or refractory NB.

      Read Full Article
      Mentions: Refractory
    14. Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

      Phase III

      Treatment

      Not yet active

      365 days to 30 years

      ANBL1531

      NCI-2016-01734, NCT03126916

      This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells.

      Read Full Article
      Mentions: Treatment INRG ALK
    15. Testing a new immunotherapy treatment for neuroblastoma

      Testing a new immunotherapy treatment for neuroblastoma

      Immunotherapies are changing the outlook for many cancer patients.

      Drugs that block cancer cells from deflecting an immune attack are now routinely used to treat advanced skin and kidney cancers, and are showing promise in other types of cancer too.

      But cancers are complex and diverse – what works well against one type of cancer might have little effect against another. The immunotherapies available for some patients aren’t a magic bullet that will work for everyone.

      Read Full Article
    16. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      Int J Cancer. 2017 Jan 15;140(2):480-484

      Authors: Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ

      Read Full Article
      Mentions: MYCN
    17. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2017 Apr 24;:

      Authors: Mody R, Zhao L, Yanik GA, Opipari V

      Abstract PURPOSE: Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Read Full Article
    18. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

      Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Eighteen HR-NBL patients with primary refractory (n = 8) or relapsed (n = 10) disease were enrolled in a Phase I study using modified Time To Event Continual Reassessment Method.

      Read Full Article
    19. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    1-24 of 175 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles